QULIPTA (AbbVie)
(https://qulipta.com) 📸 Data Snapshot: June 19, 2026Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
The site avoids typical trust theatre like unverified star ratings, which are often prohibited in pharma marketing. Instead, it uses a patient testimonial from ‘Kelsi’ with a mandatory disclosure that she was compensated, which is a regulatory honesty marker. The review_count is 0 across all pages, but the presence of two verified proof links to full prescribing information provides high-substance validation.
The proof density is high for the pharma industry. Verifiable evidence includes specific side effect percentages (constipation 6-8 percent), dose availability (10 mg, 30 mg, 60 mg), and trial duration (3-month studies). For every vague assertion of ‘more zero-migraine days,’ there is a corresponding technical specification in the body text or the Important Safety Information block.
Trust & Proof is read by weighing trust language against real verification. Below is the page-by-page tally of review mentions and external proof links, then the schema markup that may (or may not) declare verifiable ratings and identity proof.
🛡️ Trust Signals — reviews, proof links, trust-theatre check
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 0 | 2 |
| /why-qulipta/ | 0 | 2 |
| /savings-support/qulipta-complete-savings-program/ | 2 | 2 |
| /savings-support/qulipta-complete-savings-program/sign-up/ | 0 | 2 |
🔗 Identity & Technical Layer — schema JSON-LD: declared ratings, reviews & identity proof
Homepage schema
[
{
"@context": "https://schema.org",
"@type": "MedicalWebPage",
"url": "https://www.qulipta.com/",
"name": "QULIPTA® (atogepant) for Migraine Prevention",
"description": "Discover QULIPTA® (atogepant), a pill specifically designed to prevent migraine attacks in adults. See full Patient and Safety Information.",
"audience": {
"@type": "MedicalAudience",
"audiencetype": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Migraine.",
"description": "Migraine is a neurological condition characterized by recurrent headaches that can be moderate to severe in intensity. Migraine headaches are often accompanied by other symptoms such as sensitivity to light, sound, or smells, nausea, and vomiting. Migraines can be triggered by various factors such as stress, certain foods, hormonal changes, and environmental factors."
}
},
"mainEntity": {
"@type": "Drug",
"name": "QULIPTA",
"description": "QULIPTA is a once-daily pill that blocks CGRP and is approved to prevent migraine of any frequency.",
"activeIngredient": "Atogepant.",
"sameAs": "https://en.wikipedia.org/wiki/Atogepant",
"warning": "QULIPTA may affect the way other medicines work, and other medicines may affect how QULIPTA works. Before taking QULIPTA, tell your healthcare provider about all your medical conditions, including if you have kidney problems or are pregnant or plan to become pregnant.",
"manufacturer": {
"@type": "Organization",
"name": "AbbVie",
"brand": "QULIPTA",
"url": "https://www.abbvie.com",
"description": "AbbVie is a global biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines in various therapeutic areas, including immunology, oncology, neuroscience, and virology."
},
"prescribingInfo": "https://www.rxabbvie.com/pdf/qulipta_pil.pdf"
}
}
]
/why-qulipta/
[
{
"@context": "https://schema.org",
"@type": "MedicalWebPage",
"url": "https://www.qulipta.com/why-qulipta",
"name": "What Is QULIPTA® (atogepant)? - A Migraine Preventive Treatment",
"description": "Learn about QULIPTA® (atogepant), a pill that can help prevent migraine attacks in adults and keep them away over time. See full Patient & Safety Info.",
"audience": {
"@type": "MedicalAudience",
"audiencetype": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Migraine",
"description": "Migraine is a neurological condition characterized by intense, debilitating headaches."
}
},
"specialty": {
"@type": "MedicalSpecialty",
"@context": "https://schema.org",
"name": "Neurologic"
},
"mainEntity": {
"@context": "https://schema.org/",
"@type": "Drug",
"name": "QULIPTA",
"description": "QULIPTA is a once-daily pill that blocks CGRP and is approved to prevent migraine of any frequency.",
"activeIngredient": "Atogepant.",
"sameAs": "https://en.wikipedia.org/wiki/Atogepant",
"drugUnit": "mg",
"dosageForm": "Pill",
"mechanismOfAction": "QULIPTA (atogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist. It works by blocking the activity of CGRP, a protein that is involved in the development of migraines. By blocking CGRP, QULIPTA helps to prevent migraines from occurring.",
"warning": "Do not take QULIPTA if you have had an allergic reaction to atogepant or any ingredients in QULIPTA. QULIPTA may affect the way other medicines work, and other medicines may affect how QULIPTA works. Before taking QULIPTA, tell your healthcare provider about all your medical conditions, including if you have kidney problems or are on dialysis, or if you are pregnant or plan to become pregnant. Stop taking QULIPTA and get emergency medical help right away if you get any of the following symptoms, which may be part of a serious allergic reaction: swelling of the face, lips, or tongue; itching; trouble breathing; hives; or rash.",
"doseSchedule": {
"@type": "DoseSchedule",
"doseValue": [
"10",
"30",
"60"
],
"frequency": "Once daily",
"description": "Take one pill daily"
},
"drugClass": "Calcitonin gene-related peptide (CGRP) receptor antagonist.",
"manufacturer": {
"@type": "Organization",
"name": "AbbVie",
"brand": "QULIPTA",
"url": "https://www.abbvie.com",
"description": "AbbVie is a global biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines in various therapeutic areas, including immunology, oncology, neuroscience, and virology."
},
"prescribingInfo": "https://www.rxabbvie.com/pdf/qulipta_pil.pdf"
}
}
]
This page presents a snapshot of public data from QULIPTA (AbbVie), captured on June 19, 2026, to show how machine logic reads Trust & Proof signals into an AI reputation evaluation.
Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.
Notice to QULIPTA (AbbVie): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.
Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://qulipta.com to view the most current version of its content and see directly what this company is about and what it offers.